Low risk profiles in a collaborative model allows Conduct Science to assess the market with a direct to customer model. Profits are then shared, like a musical artist and royalties on song platforms. Wide swaths of potential new technologies are tested in the market and can reach customers. In smaller technical markets, this model is ideal.
Licensing raises the bar for which products may make it to market. Only a few select innovations may ever reach a customer. In some segments, like consumer healthcare, this works well.
"*" indicates required fields
Monday – Friday
9 AM – 5 PM EST
DISCLAIMER: ConductScience and affiliate products are NOT designed for human consumption, testing, or clinical utilization. They are designed for pre-clinical utilization only. Customers purchasing apparatus for the purposes of scientific research or veterinary care affirm adherence to applicable regulatory bodies for the country in which their research or care is conducted.